Coexpression ofMYCandBCL-2predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

(2013) H. Horn et al.   BLOOD

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

Gastrointestinal Lymphoma: Recent Advances in Diagnosis and Treatment

(2013) Shotaro Nakamura et al.   DIGESTION

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

(2011) J. Iqbal et al.   CLINICAL CANCER RESEARCH

Advances in the understanding of MYC-induced lymphomagenesis

(2010) Kay Klapproth et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

(2009) N. A. Johnson et al.   BLOOD

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

(2009) N Niitsu et al.   LEUKEMIA

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Myc increases self-renewal in neural progenitor cells through Miz-1

(2008) L. Kerosuo et al.   JOURNAL OF CELL SCIENCE

Apoptotic signaling by c-MYC

(2008) B Hoffman et al.   ONCOGENE

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

(2008) K. D. Mason et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA